[1]
Guillermin A, Yan DJ, Perrier A, Marti C. Safety and efficacy of tenecteplase versus alteplase in acute coronary syndrome: a systematic review and meta-analysis of randomized trials. Archives of medical science : AMS. 2016 Dec 1:12(6):1181-1187
[PubMed PMID: 27904506]
Level 1 (high-level) evidence
[2]
Murphy LR, Hill TP, Paul K, Talbott M, Golovko G, Shaltoni H, Jehle D. Tenecteplase Versus Alteplase for Acute Stroke: Mortality and Bleeding Complications. Annals of emergency medicine. 2023 May 11:():. pii: S0196-0644(23)00214-7. doi: 10.1016/j.annemergmed.2023.03.022. Epub 2023 May 11
[PubMed PMID: 37178103]
[3]
Gao L, Moodie M, Mitchell PJ, Churilov L, Kleinig TJ, Yassi N, Yan B, Parsons MW, Donnan GA, Davis SM, Campbell BCV, EXTEND-IA TNK Investigators. Cost-Effectiveness of Tenecteplase Before Thrombectomy for Ischemic Stroke. Stroke. 2020 Dec:51(12):3681-3689. doi: 10.1161/STROKEAHA.120.029666. Epub 2020 Oct 7
[PubMed PMID: 33023423]
[4]
Davydov L, Cheng JW. Tenecteplase: a review. Clinical therapeutics. 2001 Jul:23(7):982-97; discussion 981
[PubMed PMID: 11519775]
[5]
Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, Sulimov V, Rosell Ortiz F, Ostojic M, Welsh RC, Carvalho AC, Nanas J, Arntz HR, Halvorsen S, Huber K, Grajek S, Fresco C, Bluhmki E, Regelin A, Vandenberghe K, Bogaerts K, Van de Werf F, STREAM Investigative Team. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. The New England journal of medicine. 2013 Apr 11:368(15):1379-87. doi: 10.1056/NEJMoa1301092. Epub 2013 Mar 10
[PubMed PMID: 23473396]
[6]
Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A. Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vascular health and risk management. 2009:5(1):249-56
[PubMed PMID: 19436656]
[7]
Bonnefoy E, Lapostolle F, Leizorovicz A, Steg G, McFadden EP, Dubien PY, Cattan S, Boullenger E, Machecourt J, Lacroute JM, Cassagnes J, Dissait F, Touboul P, Comparison of Angioplasty and Prehospital Thromboysis in Acute Myocardial Infarction study group. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet (London, England). 2002 Sep 14:360(9336):825-9
[PubMed PMID: 12243916]
Level 1 (high-level) evidence
[8]
Boden WE, Eagle K, Granger CB. Reperfusion strategies in acute ST-segment elevation myocardial infarction: a comprehensive review of contemporary management options. Journal of the American College of Cardiology. 2007 Sep 4:50(10):917-29
[PubMed PMID: 17765117]
[9]
Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, Hochman JS, Krumholz HM, Lamas GA, Mullany CJ, Pearle DL, Sloan MA, Smith SC Jr, 2004 Writing Committee Members, Anbe DT, Kushner FG, Ornato JP, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation. 2008 Jan 15:117(2):296-329
[PubMed PMID: 18071078]
Level 1 (high-level) evidence
[10]
Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet (London, England). 2006 Feb 18:367(9510):569-78
[PubMed PMID: 16488800]
Level 1 (high-level) evidence
[11]
Armstrong PW, WEST Steering Committee. A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. European heart journal. 2006 Jul:27(13):1530-8
[PubMed PMID: 16757491]
[12]
Fernández-Avilés F, Alonso JJ, Peña G, Blanco J, Alonso-Briales J, López-Mesa J, Fernández-Vázquez F, Moreu J, Hernández RA, Castro-Beiras A, Gabriel R, Gibson CM, Sánchez PL, GRACIA-2 (Groupo de Análisis de Cardiopatía Isquémica Aguda) Investigators. Primary angioplasty vs. early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, controlled trial. European heart journal. 2007 Apr:28(8):949-60
[PubMed PMID: 17244641]
Level 1 (high-level) evidence
[13]
Yogendrakumar V, Churilov L, Guha P, Beharry J, Mitchell PJ, Kleinig TJ, Yassi N, Thijs V, Wu TY, Brown H, Dewey HM, Wijeratne T, Yan B, Sharma G, Desmond PM, Parsons MW, Donnan GA, Davis SM, Campbell BCV, EXTEND-IA TNK Investigators. Tenecteplase Treatment and Thrombus Characteristics Associated With Early Reperfusion: An EXTEND-IA TNK Trials Analysis. Stroke. 2023 Mar:54(3):706-714. doi: 10.1161/STROKEAHA.122.041061. Epub 2023 Feb 2
[PubMed PMID: 36727510]
[14]
Kvistad CE, Næss H, Helleberg BH, Idicula T, Hagberg G, Nordby LM, Jenssen KN, Tobro H, Rörholt DM, Kaur K, Eltoft A, Evensen K, Haasz J, Singaravel G, Fromm A, Thomassen L. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial. The Lancet. Neurology. 2022 Jun:21(6):511-519. doi: 10.1016/S1474-4422(22)00124-7. Epub 2022 May 4
[PubMed PMID: 35525250]
Level 1 (high-level) evidence
[15]
Huang X, Cheripelli BK, Lloyd SM, Kalladka D, Moreton FC, Siddiqui A, Ford I, Muir KW. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. The Lancet. Neurology. 2015 Apr:14(4):368-76. doi: 10.1016/S1474-4422(15)70017-7. Epub 2015 Feb 26
[PubMed PMID: 25726502]
Level 1 (high-level) evidence
[16]
Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, O'Brien B, Bladin C, McElduff P, Allen C, Bateman G, Donnan G, Davis S, Levi C. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. The New England journal of medicine. 2012 Mar 22:366(12):1099-107. doi: 10.1056/NEJMoa1109842. Epub
[PubMed PMID: 22435369]
[17]
Kheiri B, Osman M, Abdalla A, Haykal T, Ahmed S, Hassan M, Bachuwa G, Al Qasmi M, Bhatt DL. Tenecteplase versus alteplase for management of acute ischemic stroke: a pairwise and network meta-analysis of randomized clinical trials. Journal of thrombosis and thrombolysis. 2018 Nov:46(4):440-450. doi: 10.1007/s11239-018-1721-3. Epub
[PubMed PMID: 30117036]
Level 1 (high-level) evidence
[18]
Tsivgoulis G, Katsanos AH, Christogiannis C, Faouzi B, Mavridis D, Dixit AK, Palaiodimou L, Khurana D, Petruzzellis M, Psychogios K, Macleod MJ, Ahmed N. Intravenous Thrombolysis with Tenecteplase for the Treatment of Acute Ischemic Stroke. Annals of neurology. 2022 Sep:92(3):349-357. doi: 10.1002/ana.26445. Epub 2022 Jul 7
[PubMed PMID: 35713213]
[19]
Menon BK, Buck BH, Singh N, Deschaintre Y, Almekhlafi MA, Coutts SB, Thirunavukkarasu S, Khosravani H, Appireddy R, Moreau F, Gubitz G, Tkach A, Catanese L, Dowlatshahi D, Medvedev G, Mandzia J, Pikula A, Shankar J, Williams H, Field TS, Manosalva A, Siddiqui M, Zafar A, Imoukhuede O, Hunter G, Demchuk AM, Mishra S, Gioia LC, Jalini S, Cayer C, Phillips S, Elamin E, Shoamanesh A, Subramaniam S, Kate M, Jacquin G, Camden MC, Benali F, Alhabli I, Bala F, Horn M, Stotts G, Hill MD, Gladstone DJ, Poppe A, Sehgal A, Zhang Q, Lethebe BC, Doram C, Ademola A, Shamy M, Kenney C, Sajobi TT, Swartz RH, AcT Trial Investigators. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet (London, England). 2022 Jul 16:400(10347):161-169. doi: 10.1016/S0140-6736(22)01054-6. Epub 2022 Jun 29
[PubMed PMID: 35779553]
Level 1 (high-level) evidence
[20]
Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, Tirschwell DL. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2019 Dec:50(12):e344-e418. doi: 10.1161/STR.0000000000000211. Epub 2019 Oct 30
[PubMed PMID: 31662037]
[21]
Zhang Z, Xi L, Zhang S, Zhang Y, Fan G, Tao X, Gao Q, Xie W, Yang P, Zhai Z, Wang C. Tenecteplase in Pulmonary Embolism Patients: A Meta-Analysis and Systematic Review. Frontiers in medicine. 2022:9():860565. doi: 10.3389/fmed.2022.860565. Epub 2022 Mar 31
[PubMed PMID: 35433747]
Level 1 (high-level) evidence
[22]
Igneri LA, Hammer JM. Systemic Thrombolytic Therapy for Massive and Submassive Pulmonary Embolism. Journal of pharmacy practice. 2020 Feb:33(1):74-89. doi: 10.1177/0897190018767769. Epub 2018 Apr 19
[PubMed PMID: 29673293]
[23]
Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, Bluhmki E, Bouvaist H, Brenner B, Couturaud F, Dellas C, Empen K, Franca A, Galiè N, Geibel A, Goldhaber SZ, Jimenez D, Kozak M, Kupatt C, Kucher N, Lang IM, Lankeit M, Meneveau N, Pacouret G, Palazzini M, Petris A, Pruszczyk P, Rugolotto M, Salvi A, Schellong S, Sebbane M, Sobkowicz B, Stefanovic BS, Thiele H, Torbicki A, Verschuren F, Konstantinides SV, PEITHO Investigators. Fibrinolysis for patients with intermediate-risk pulmonary embolism. The New England journal of medicine. 2014 Apr 10:370(15):1402-11. doi: 10.1056/NEJMoa1302097. Epub
[PubMed PMID: 24716681]
[24]
Warach SJ, Dula AN, Milling TJ Jr. Tenecteplase Thrombolysis for Acute Ischemic Stroke. Stroke. 2020 Nov:51(11):3440-3451. doi: 10.1161/STROKEAHA.120.029749. Epub 2020 Oct 13
[PubMed PMID: 33045929]
[25]
Fugate JE, Rabinstein AA. Absolute and Relative Contraindications to IV rt-PA for Acute Ischemic Stroke. The Neurohospitalist. 2015 Jul:5(3):110-21. doi: 10.1177/1941874415578532. Epub
[PubMed PMID: 26288669]
[27]
Mehta RH, Alexander JH, Van de Werf F, Armstrong PW, Pieper KS, Garg J, Califf RM, Granger CB. Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes. JAMA. 2005 Apr 13:293(14):1746-50
[PubMed PMID: 15827313]
Level 2 (mid-level) evidence